Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Free Cash Flow (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Free Cash Flow for 11 consecutive years, with -$69.4 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 14.28% to -$69.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$395.9 million through Dec 2025, down 13.28% year-over-year, with the annual reading at -$395.9 million for FY2025, 13.28% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$69.4 million at Intellia Therapeutics, up from -$76.9 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$54.7 million in Q4 2021, with the low at -$149.7 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$86.3 million, with a median of -$84.3 million recorded in 2022.
  • The sharpest move saw Free Cash Flow tumbled 199.18% in 2021, then soared 40.68% in 2024.
  • Over 5 years, Free Cash Flow stood at -$54.7 million in 2021, then tumbled by 85.15% to -$101.2 million in 2022, then fell by 4.19% to -$105.5 million in 2023, then rose by 23.24% to -$81.0 million in 2024, then increased by 14.28% to -$69.4 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$69.4 million, -$76.9 million, and -$99.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.